Anxo Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Anxo Pharmaceutical's earnings have been declining at an average annual rate of -15.8%, while the Pharmaceuticals industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 1.1% per year. Anxo Pharmaceutical's return on equity is 2.6%, and it has net margins of 2.3%.
Key information
-15.8%
Earnings growth rate
-17.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 1.1% |
| Return on equity | 2.6% |
| Net Margin | 2.3% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses Breakdown
How Anxo Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 940 | 22 | 204 | 139 |
| 30 Sep 23 | 941 | 28 | 199 | 141 |
| 30 Jun 23 | 941 | 33 | 193 | 144 |
| 31 Mar 23 | 904 | 10 | 190 | 142 |
| 31 Dec 22 | 866 | -13 | 186 | 140 |
| 30 Sep 22 | 830 | -17 | 183 | 134 |
| 30 Jun 22 | 793 | -21 | 180 | 127 |
| 31 Mar 22 | 809 | -1 | 180 | 119 |
| 31 Dec 21 | 824 | 19 | 180 | 111 |
| 30 Sep 21 | 835 | 19 | 185 | 111 |
| 30 Jun 21 | 845 | 19 | 191 | 110 |
| 31 Mar 21 | 856 | 25 | 195 | 105 |
| 31 Dec 20 | 866 | 31 | 199 | 101 |
| 30 Sep 20 | 867 | 25 | 199 | 88 |
| 30 Jun 20 | 867 | 19 | 200 | 76 |
| 31 Mar 20 | 873 | 22 | 204 | 71 |
| 31 Dec 19 | 878 | 24 | 207 | 67 |
| 30 Sep 19 | 863 | 20 | 208 | 66 |
| 30 Jun 19 | 847 | 16 | 208 | 64 |
| 31 Mar 19 | 849 | 22 | 211 | 68 |
| 31 Dec 18 | 850 | 29 | 214 | 71 |
| 30 Sep 18 | 823 | 20 | 216 | 70 |
| 30 Jun 18 | 795 | 11 | 218 | 69 |
| 31 Mar 18 | 750 | -9 | 218 | 63 |
| 31 Dec 17 | 705 | -29 | 218 | 57 |
| 30 Sep 17 | 692 | -22 | 218 | 58 |
| 30 Jun 17 | 679 | -15 | 219 | 59 |
| 31 Mar 17 | 660 | -17 | 218 | 57 |
| 31 Dec 16 | 642 | -20 | 218 | 56 |
| 31 Dec 15 | 631 | -24 | 209 | 31 |
| 31 Dec 14 | 643 | 26 | 185 | 27 |
Quality Earnings: 6677 has high quality earnings.
Growing Profit Margin: 6677 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6677's earnings have declined by 15.8% per year over the past 5 years.
Accelerating Growth: 6677 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 6677 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 6677's Return on Equity (2.6%) is considered low.